Replies to post #143226 on Biotech Values

[NP1986]

I don't disagree with your argument about limited reimbursement dollars, but it could be made for any therapeutic area.

I think if there is a genuine unmet medical need, it would be hard for governments or insurers to refuse to pay for a drug that works, and compromises will ultimately have to be made in other areas.

[masterlongevity]

yes, and the idea that reimbursment is a clear hurdle will change dramatically over th nxt 10 yrs

[masterlongevity]

i also think the clinical successs will be lower for the 1000 drugs in development than ite was in the past. In the gold rush that has ensued, there are a lot of people develping "drugs' that have no idea what thy are doing.

[BuyOnDips]

At this point in time, I fully agree with your statment. Very postive results, but not yet FDA approved.

Quote
In short, there simply aren’t going to be that many Ponatinibs.